Singapore markets open in 4 hours 23 minutes

Aligos Therapeutics, Inc. (ALGS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8236+0.0226 (+2.82%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.8010
Open0.8015
Bid0.8236 x 300
Ask0.8676 x 100
Day's range0.8015 - 0.8977
52-week range0.5390 - 1.3800
Volume96,855
Avg. volume393,619
Market cap62.321M
Beta (5Y monthly)2.34
PE ratio (TTM)N/A
EPS (TTM)-1.3600
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

    SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024. Please contact your Piper Sandler representative to sched

  • GlobeNewswire

    Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

    SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH). “Dosing the first subjects in our Phase 2a HERALD study is an important mile

  • Zacks

    Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

    Is it a good or bad thing when a stock experiences a golden cross technical event?